EDIT-101

DB18687InvestigationalGene Therapies

EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.

Mechanism: Pharmacologically active on Centrosomal protein of 290 kDa
Curator reviewed
Also known as: a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs
Code names: EDIT-101

Resolves to

Compound

UNII4G7DT7PP3L

Targets

O15078CEP290

What you can answer from here — as of October 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with EDIT-101, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account